Polychemotherapy AVB schema in Kaposi's sarcoma in HIV-infected patients (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Polychemotherapy AVB schema in Kaposi's sarcoma in HIV-infected patients (Meeting abstract).

Ann Oncol; 3(Suppl 5):136 1992. Unique Identifier : AIDSLINE ICDB/93689687
Munarriz J; Mohedano N; Jimenez U; Donnay O; Lazaro M; Sanz J; Verdejo J; Martinez MC; Castrillo JM; Guardiola L; et al; S. Oncologia Medica-E, Infecciosas, Hosp. de la Princesa, Madrid,; Spain

Abstract: Chemotherapy was planned on those HIV+ patients (pts) with Kaposi's sarcoma (KS) with unfavorable prognostic factors. In a first group which showed rapid progression with CD4 A and with skin affects, chemotherapy was carried out with vincristine/vinblastine (VBL). In a second group with III/IV stages, CD4 200 and prior opportunistic infections polychemotherapy AVB schema (Adriamycin [ADR], vincristine [VCR], bleomycin [Bleo]) was performed. Materials and methods: 16 pts with KS were studied; they had an av age of 35 yr (26-44). A total of 10 pts showed Stage II (cutaneous and mucocutaneous localizations), and 6 were Stages III-IV metastatic localizations in the lungs and digestive systems. Of the 16 pts, 12 received the AVB schema (ADR 20 mg/m x 1, VCR 2 mg/m x 1 and Bleo 10 mg/m x 1 at 14-day intervals), and 4 received the alternating VCR/VBL schema. The av cycle per pt was 5. Results: 10 pts were evaluated with the AVB schema. In 6 of them (60%), a partial response in skin lesions was obtained with depigmentation and a lessening of the lesions, with an av duration of approx 3 mo. The most significant collateral results were severe pancytopenia in 4 pts and an important number of accumulated infections (6 with pneumonia, cerebral toxoplasmosis 1, pulmonary TB, herpes zoster 2, and Candida, 4). Conclusions: Although the number of pts is not very important, we think that chemotherapy provides an objective improvement in 50% of the pts within a very short period of time, and that these kinds of pts show a high number of accumulated infectious processes that impede the carrying out of adequate chemotherapy.

Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Adult Antineoplastic Agents, Combined/*THERAPEUTIC USE Bleomycin/ADMINISTRATION & DOSAGE Doxorubicin/ADMINISTRATION & DOSAGE Sarcoma, Kaposi's/*DRUG THERAPY/ETIOLOGY Vincristine/ADMINISTRATION & DOSAGE ABSTRACT
930430
M9340819

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .